Ledraxen (Enoxaparin Sodium)

Ledraxen, a low molecular weight heparin, is indicated for several thrombo‑embolic conditions.

• Deep vein thrombosis (surgical prophylaxis): prevents clot formation in postoperative patients.
• Acute deep vein thrombosis (treatment): facilitates clot resolution and reduces propagation.
• Pulmonary embolism (prevention and treatment): lowers the risk of embolic events in at‑risk individuals.
• Haemodialysis anticoagulation: maintains circuit patency during renal replacement therapy.

• Enoxaparin Sodium potentiates antithrombin III, enhancing its inhibition of activated factor Xa and, to a lesser extent, factor IIa (thrombin). This selective blockade reduces thrombin generation and fibrin formation, thereby interrupting the coagulation cascade and preventing clot extension and new clot formation.

Adverse reactions may occur with any anticoagulant therapy.

Common Side Effects

• Injection site pain or erythema: mild discomfort at the injection site.
• Bruising or hematoma: localized bleeding under the skin.
• Minor bleeding: epistaxis, gum bleeding, or easy bruising.
• Nausea or gastrointestinal upset.
• Headache or dizziness.

Serious or Rare Side Effects

• Major bleeding: internal hemorrhage, gastrointestinal or intracranial bleeding.
• Thrombocytopenia (HIT): sudden drop in platelet count with paradoxical clotting risk.
• Spinal or epidural hematoma: especially after neuraxial procedures.
• Severe allergic reaction: urticaria, angioedema, or anaphylaxis.
• Elevated liver enzymes: indicating hepatic involvement.

Use of Ledraxen requires careful clinical assessment.

• Renal impairment: adjust dose or monitor anti‑Xa levels in patients with reduced kidney function.
• Hepatic disease: consider increased bleeding risk in severe liver dysfunction.
• Concomitant anticoagulants: avoid or closely monitor when used with warfarin, direct oral anticoagulants, or antiplatelet agents.
• Recent surgery or trauma: assess bleeding risk before initiating therapy.
• Pregnancy and breastfeeding: safety not established; use only if benefit outweighs risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin may interact with several drug classes, influencing bleeding risk.

Major Interactions (Avoid)

• Other anticoagulants (e.g., unfractionated heparin, direct thrombin inhibitors): additive anticoagulant effect.
• Antiplatelet agents (aspirin, clopidogrel, ticagrelor): increased bleeding tendency.
• Fibrinolytic therapy (tPA, streptokinase): heightened hemorrhagic risk.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): potentiates mucosal bleeding.
• Neuraxial anesthesia or spinal puncture: risk of spinal/epidural hematoma.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: monitor for hypotension if combined with significant blood loss.
• Renal‑clearing drugs (e.g., aminoglycosides): watch for accumulation in renal impairment.
• Platelet transfusions: may affect platelet counts and clotting dynamics.